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AbstrAct
Objective Inoperable chronic thromboembolic pulmonary 
hypertension (CTEPH) managed medically has a poor 
prognosis. Balloon pulmonary angioplasty (BPA) offers a new 
treatment for inoperable patients. The national BPA service 
for the UK opened in October 2015 and we now describe the 
treatment of our initial patient cohort.
Methods Thirty consecutive, inoperable, anatomically 
suitable, symptomatic patients on stable medical therapy 
for CTEPH were identified and offered BPA. They initially 
underwent baseline investigations including Cambridge 
Pulmonary Hypertension Outcome Review (CAMPHOR) 
quality of life (QoL) questionnaire, cardiopulmonary 
exercise test, 6 min walk distance (6MWD), transthoracic 
echocardiography, N- terminal probrain natriuretic peptide 
(NT pro- BNP) and right heart catheterisation. Serial BPA 
sessions were then performed and after completion, the 
treatment effect was gauged by comparing the same 
investigations at 3 months follow- up.
Results A median of 3 (IQR 1–6) BPA sessions per patient 
resulted in a significant improvement in functional status 
(WHO functional class ≥3: 24 vs 4, p<0.0001) and QoL 
(CAMPHOR symptom score: 8.7±5.4 vs 5.6±6.1, p=0.0005) 
with reductions in pulmonary pressures (mean pulmonary 
artery pressure: 44.7±11.0 vs 34.4±8.3 mm Hg, p<0.0001) 
and resistance (pulmonary vascular resistance: 663±281 vs 
436±196  dyn. s. cm-5, p<0.0001). Exercise capacity improved 
(minute ventilation/carbon dioxide production: 55.3±12.2 
vs 45.0±7.8, p=0.03 and 6MWD: 366±107 vs 440±94 m, 
p<0.0001) and there was reduction in right ventricular (RV) 
stretch (NT pro- BNP: 442 (IQR 168–1607) vs 202 (IQR 105–
447) pg/mL, p<0.0001) and dimensions (mid RV diameter: 
4.4±1.0 vs 3.8±0.7 cm, p=0.002). There were no deaths or 
life- threatening complications and the mild- moderate per- 
procedure complication rate was 10.5%.
Conclusions BPA is safe and improves the functional status, 
QoL, pulmonary haemodynamics and RV dimensions of 
patients with inoperable CTEPH.
IntROduCtIOn
Chronic thromboembolic pulmonary hyper-
tension (CTEPH) is a condition caused by 
failure of resolution of pulmonary emboli (PE) 
and results in fibrotic tissue deposition that 
Key questions
What is already known about this subject?
 ► Balloon pulmonary angioplasty (BPA) is emerging 
as a viable treatment for patients with inoperable 
chronic thromboembolic pulmonary hypertension 
(CTEPH). Studies have shown it improves symp-
toms, pulmonary haemodynamics and in a limit-
ed number of series right heart size and function. 
However, many of the patients treated to date would 
have received pulmonary endarterectomy (PEA) in 
the UK, and therefore, it was important to confirm 
the therapeutic effect of BPA on a UK cohort of pa-
tients with inoperable CTEPH.
What does this study add?
 ► We describe the initial UK experience of BPA deliv-
ered within the national CTEPH service with a high-
ly experienced PEA surgical service. We show that 
BPA performed in patients with inoperable disease, 
on established PH- targeted therapy and delivered 
with a focused approach (targeting predominantly 
basal subsegmental disease distribution and with 
fewer treatment cycles than previous reports) safely 
derives benefits of comparable magnitude to oth-
er series. We also demonstrate for the first time 
improvement in patient quality of life measured 
by Cambridge Pulmonary Hypertension Outcome 
Review questionnaire and provide compelling data 
on improvements in cardiopulmonary exercise 
testing, biomarker levels and right ventricular re-
modelling/function which are important prognostic 
surrogates.
How might this impact on clinical practice?
 ► These data clearly show BPA is an effective and safe 
treatment for patients with inoperable CTEPH. We 
believe that BPA is now sufficiently developed that 
appropriately powered randomised controlled trials 
comparing subsegmental PEA verses BPA and BPA 
verses PH- targeted therapy can be planned to guide 
optimal treatment strategy for patients with CTEPH.
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occludes the pulmonary arteries.1 CTEPH has an incidence 
of 0.9–5.7 cases per million and a prevalence of 8–40 cases 
per million although this is likely to be an underestimate 
as the condition is often under- reported.2 3 It has been esti-
mated that between 0.56% and 3% of acute PE develop 
CTEPH.4 Mechanical obstructions and secondary pulmo-
nary vasculopathy cause pulmonary hypertension, right 
ventricular (RV) remodelling and dilatation culminating in 
a worsening exercise tolerance, right heart failure and early 
death.5 Survival at 3 years in unoperated patients is 70% 
and is not affected by medical therapy, although prelimi-
nary data suggest that the soluble guanylate cyclase (sGC) 
riociguat may improve medium- term survival.6
Pulmonary endarterectomy (PEA) is an established 
therapeutic intervention and is the guideline recom-
mended treatment for patients with CTEPH.7–9 It is, 
however, a major surgical procedure and associated 
with an intraoperative mortality of around 2.2% and a 
major complication rate of nearly 50%, even in the most 
experienced centres and therefore for some the risks 
may outweigh the potential benefit.10 In addition, due 
to distal distribution of thromboembolic changes, PEA 
may not be technically feasible. As a result approximately 
40% of patients are inoperable and of those undergoing 
PEA 20% may have incomplete clearance and persistent 
functional limitation.11 Those patients with inoperable or 
residual CTEPH may either be treated with PH—targeted 
medical therapy, for which there is short- medium term 
evidence of haemodynamic and symptomatic improve-
ment12–15 and/or balloon pulmonary angioplasty (BPA) 
for which there is only observational evidence to date.16 17
BPA is a novel technique, initially described by Fein-
stein et al18 in the USA and then refined in Japan and 
Europe over the past 15 years,19 where balloon mounted 
catheters are introduced over a guide wire into pulmo-
nary segmental and subsegmental diseased vessels and 
inflated to unblock them and restore flow. Contempo-
rary data provide compelling evidence of the benefits of 
BPA with improvements in both symptoms and haemody-
namics noted.20 Meta- analysis data suggest that the effects 
of BPA may be superior to medical therapy and possibly 
equivalent to PEA,16 although no randomised control 
data comparing treatment strategies has been published 
to date. Reassuringly the effects of BPA appear durable 
out to 5 years, with restenosis being a rare occurrence.21 22 
However, the reported therapeutic effect of BPA may be 
affected by the phenotypic differences in those offered 
BPA; many patients included in the early BPA studies had 
surgically operable disease. The effect of BPA in patients 
with inoperable disease and residual disease after PEA 
remains uncertain, as does the optimal interventional 
strategy employed and further studies are required.
MetHOds
new service and patient pathway
The national BPA service at Royal Papworth Hospital, 
which also hosts the national CTEPH service and has 
one of the largest PEA experiences worldwide, was set 
up in 2015 supported by a charitable grant. Patients 
with CTEPH are referred to the national CTEPH multi-
disciplinary team (MDT) meeting for initial considera-
tion of PEA. Only patients deemed inoperable but who 
potentially have BPA- treatable disease are invited for a 
conventional pulmonary angiogram and rediscussion at 
a BPA MDT meeting. Patients are accepted only if symp-
tomatically limited despite PH- targeted medical therapy 
and where territories with normal or near normal lung 
parenchyma have reduced lung perfusion subtended 
by anatomically treatable vessels evident on pulmonary 
angiography without procedural contraindications, 
for example, contrast allergy, severe renal dysfunction, 
inability to breath- hold or access- site issues. To maximise 
symptomatic and haemodynamic benefit as well as the 
available limited resources, a targeted approach has been 
employed, preferentially selecting lower lobe vessels as 
the primary targets for BPA. Those accepted for BPA 
are invited to clinic for detailed counselling and written 
patient information, included within a bespoke consent 
form. Those patients who agree to proceed are then 
listed for their procedure.
As per international guidelines,23 prior to the first 
procedure patients are maintained on PH- targeted 
therapy and this is not modified during the periproce-
dural period. Patients then undergo a series of clinically 
driven preprocedural tests the day before their first BPA 
procedure that include: cardiopulmonary exercise test 
(CPET), transthoracic echo, pulmonary function test, 
blood tests including N- terminal probrain natriuretic 
peptide (NT- proBNP), 6 min walk distance (6MWD), 
assessment of functional class (FC), Cambridge Pulmo-
nary Hypertension Outcome Review (CAMPHOR)—a 
disease- specific patient- reported assessment of quality of 
life (QoL), where a high score indicates worse symptoms, 
activity level and QoL24 and right heart catheter (immedi-
ately prior to their first BPA). At completion of treatment, 
they are invited back at 3 months follow- up for assessment 
of their response guided by repeating the above tests.
treatment algorithm
This report includes the first 30 consecutive patients 
treated by BPA at our centre between October 2015 and 
April 2018.
Preprocedure
Patients stop warfarin 5 days before their procedure 
and were commenced on bridging, therapeutic dose, 
low- molecular- weight heparin (LMWH) until the day 
before admission if their INR (International Normal-
ised Ratio) was <2. Where a direct oral anticoagulant was 
used these were omitted the day before the procedure 
without LMWH bridging. In addition to the investiga-
tions mentioned above, blood for renal function, haemo-
globin, INR (for those on warfarin) and cross- matching 
was drawn. Patients were nil by mouth for 8 hours before 
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Figure 1 Patient flow through the National CTEPH service. 
BPA, balloon pulmonary angioplasty; CTEPH, chronic 
thromboembolic pulmonary hypertension; PEA, pulmonary 
endarterectomy.
the procedure, although clear fluid was permitted up to 
4 hours.
BPA procedure
Procedures were performed under conscious sedation 
(remifentanyl initially to suppress cough and then mida-
zolam) with anaesthetic support. Oxygen was supplied 
via nasal cannulae and the saturations monitored non- 
invasively. In our early experience, a radial arterial sheath 
was used to monitor systemic pressure during the proce-
dure but this was quickly abandoned. A 6 French sheath 
was then placed in the right femoral vein under local 
anaesthesia and unfractionated heparin (70–100 IU/
kg) was administered. Activated clotting time (ACT) was 
measured after 1 hour if the procedure was prolonged 
and further heparin administered to achieve an ACT 
>250 s.
Right heart catheterisation including thermodilution 
cardiac output assessment (Swan- Ganz catheter, Edwards 
Lifesciences, Irvine, USA) was performed at the begin-
ning of each procedure as standard. The venous sheath 
was then exchanged for an 80 cm Shuttle Sheath (Cook 
Medical, Limerick, Ireland) guided by an angled pigtail 
catheter (Cardinal Health, Dublin, USA) to advance 
it into the pulmonary artery to provide guide catheter 
stability required for the intervention. A digital subtrac-
tion cine of the relevant lobe performed (right anterior 
oblique 30o for the left pulmonary artery and left anterior 
oblique 30o for the right pulmonary artery to guide the 
intervention). A long 150 cm exchange length 0.035 inch 
wire was then used to maintain segmental pulmonary 
artery position and replace the angled pigtail catheter 
for either a multipurpose or Judkins right four catheters 
(Cardinal Health). Subsegmental vessels were then wired 
with a Whisper medium support wire or occasionally a 
Pilot 50 wire (Abbott Vascular, Santa Clara, USA) and 
the lesions were balloon dilated with a 2–4 mm x 20 mm 
Trek balloon (Abbott Vascular) inflated to between 2 and 
8 atmospheres. During the initial learning phase only 
simple discreet web lesions in one segmental territory 
were treated per session, but, as experience increased, 
disease of all types (webs, slits, stenoses and occlusions) 
were treated and when the haemodynamic were favour-
able (mean PA pressure <40 mm Hg) multiple lesions 
within the same lobe were cleared in a single session, 
although none had bilateral BPA in the same sitting.
Postprocedure
Patients invariably had the femoral venous sheath 
removed in the catheter lab at the end of the proce-
dure and initially had saturations monitored in a high 
dependency unit setting overnight. A chest radiograph 
was also routinely requested to assess for early radiolog-
ical evidence of reperfusion oedema or bleeding. More 
recently patients have been observed in a theatre recovery 
for an hour and then returned to the respiratory ward for 
4 hours bed rest. Patients with an uncomplicated proce-
dure are recommenced on their oral anticoagulant (with 
LMWH bridging for those treated with warfarin until the 
INR is >2) and PH- targeted therapy on the same evening 
as their procedure and are usually discharged the next 
day.
Repeated sessions following the same treatment algo-
rithm were performed at monthly intervals as long as 
there remained suitable targets for BPA and patients 
continued to be symptomatic. This interval treatment 
limited to one side at a time minimises the risk of compli-
cations. At completion patients were invited back for 
review at a 3- month follow- up appointment.
statistical analysis
To assess the efficacy of BPA, the clinical parame-
ters recorded at baseline and 3- month follow- up were 
compared. Categorical variables were presented as 
numbers and percentages and compared with the use 
of the X2 test or Fisher’s exact test. Continuous variables 
were compared as means (SD) with Student’s t- test for 
normally distributed data or median (IQR) by Pearson’s 
coefficient for non- parametric data, as appropriate. A 
two- sided p<0.05 was considered to indicate statistical 
significance.
Results
The number of referrals to the national CTEPH MDT 
meeting between October 2015 and April 2018 and 
their subsequent allocation to therapy is summarised 
in figure 1. Of the 943 patients with CTEPH referred, 
389 patients had inoperable disease and 93 were then 
considered for BPA at the MDT meeting. Of these, 47 
patients were offered BPA. Four patients declined, 13 
were awaiting BPA and 30 completed a course of BPA 
treatment within the time period and attended for 
3- month follow- up. These 30 patients had a mean age 
Open Heart
4 Hoole SP, et al. Open Heart 2020;7:e001144. doi:10.1136/openhrt-2019-001144
Table 1 Haemodynamic indices, functional status and right heart function at baseline and at 3 months follow- up after BPA 
treatment
Variable Baseline Follow- up P value
Haemodynamics
  RAP, mm Hg 9.4±4.1 5.1±2.7 <0.0001
  RVEDP, mm Hg 12.4±5.7 6.4±2.5 <0.0001
  mPAP, mm Hg 44.7±11.0 34.4±8.3 <0.0001
  COTD, L/min 4.4±1.1 4.8±1.1 0.03
  PVRTD, dyn.s/cm
5 663±281 436±196 <0.0001
Functional status
  VO2 max, mL/min/kg 16.9±3.4 18.9±4.5 0.002
  VE/VCO2 55.3±12.2 45.0±7.8 0.03
  6MWT, metres 366±107 440±94 <0.0001
  WHO FC ≥3, n (%) 24 (80) 4 (13) <0.0001
  CAMPHOR symptom score 8.7±5.4 5.6±6.1 0.0005
Right heart function
  NT pro- BNP, pg/mL 442 (168,1607) 202 (105 to 447) <0.0001
  RV d mid- diameter, cm 4.4±1.0 3.8±0.7 0.002
  RV d area, cm2 31.9±7.6 28.2±7.4 0.003
  RV FAC, % 24.4±6.2 31.3±9.1 0.0001
  RV systolic velocity, cm/s 11.5±3.0 13.2±3.2 0.03
  Diastolic EI 1.3±0.3 1.1±0.2 0.001
  Systolic EI 1.5±0.5 1.3±0.4 0.004
BPA, balloon pulmonary angioplasty; CAMPHOR, Cambridge Pulmonary Hypertension Outcome Review; COTD, cardiac output by 
thermodilution; d, diastolic; EI, Eccentricity Index; FAC, fractional area change; mPAP, mean pulmonary artery pressure; 6MWT, 6 min walk 
test; NT- Pro BNP, N- terminal probrain natriuretic peptide; PVRTD, pulmonary vascular resistance by thermodilution; RAP, right atrial pressure; 
RV, right ventricular; RVEDP, right ventricular end- diastolic pressure; VE/VCO2, minute ventilation/ carbon dioxide production (ventilator 
efficiency); VO2, oxygen consumption; WHO FC, WHO functional class.
of 63.5±11.6 years and were predominantly male (n=22, 
73%). All were anticoagulated and most were taking 
PH- targeted therapy (no therapy (did not tolerate): n=2; 
monotherapy: phosphodiesterase inhibitor (PDEi) n=12, 
endothelin receptor antagonist (ERA) n=1, sGC n=7; 
combination therapy: ERA+PDEi n=6, ERA +sGC n=2) 
that was not altered during their BPA treatment cycles 
and follow- up. Despite these drug therapies, patients 
remained highly symptomatic before BPA, as evidenced 
by a baseline WHO FC of 3 in 24/30 (80%) and a mean 
CAMPHOR symptom score of 8.7 at baseline. Their base-
line pulmonary haemodynamics were deranged with a 
mean pulmonary artery pressure (mPAP) of 44 mm Hg 
and a pulmonary vascular resistance (PVR) of 660 dyn.s/
cm5, as well as evidence of a pressure loaded right 
ventricle with dilatation, altered geometry and early signs 
of RV decompensation (table 1).
A total of 95 procedures were undertaken and patients 
were treated with a median of 3 (IQR 1–6) BPA treatment 
cycles at monthly intervals focusing predominantly on 
the basal segmental and sub- segmental vessels; the total 
number of vessels treated was 198, equally distributed 
between left and right lung with 183/198 (92%) lesions 
located in an anterior basal (A8), lateral basal (A9) and 
posterior (A10) basal arteries of both lungs.
A course of BPA universally improved all haemody-
namic parameters (table 1) and in particular significant 
reductions in mPAP (−21.9±14.1%, p<0.0001) and PVR 
(−32.4±18.6%, p<0.0001) were observed with more modest 
improvements in cardiac output (figure 2). This resulted 
in significant increases in exercise capacity measured by 
6MWD (+21.2% ± 27.0%, p<0.0001) and ventilatory effi-
ciency that resulted in an improvement in FC (figure 3) 
and CAMPHOR score (table 1). The improvement in 
CAMPHOR was primarily driven by improvement in 
symptom score (Δ −3.1±4.0, p=0.0005) and activity score 
(Δ −1.6±3.6, p=0.03) rather than QoL score per se (Δ 
−1.5±4.8, p=0.11). There was clear biomarker evidence of 
reduced right heart strain quantified by a reduction in 
NT- proBNP (−38.4±42.5%, p<0.0001) as well as reverse 
RV remodelling with beneficial changes in RV geometry, 
reductions in RV size and improvement in RV function 
(table 1 and figure 4).
This patient benefit came at minimal cost. There were no 
deaths or life- threatening complications and nor did any 
patient require intensive care or emergency intubation. 
In total there were 10 mild- moderate procedure- related 
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Figure 2 Haemodynamic effect of BPA treatment on (A) mean PAP (B) CO measured by thermodilution and (C) PVR measured 
by thermodilution. BAP, balloon pulmonary angioplasty; COTD, cardiac output by thermodilution; PAP, pulmonary artery 
pressure; PVR, pulmonary vascular resistance.
Figure 3 Change in WHO FC of the initial 30 patients 
treated by BPA. BPA, balloon pulmonary angioplasty; FC, 
functional class.
complications (a per- procedure rate of 10.5%). There 
were two access site haematoma, one of which required 
surgical exploration and a blood transfusion. There were 
also eight acute lung injuries composed of five proce-
dures complicated by mild haemoptysis (three from distal 
wire perforations, one of which required placement of a 
haemostatic coil) and three procedures with lung reper-
fusion oedema confirmed by chest radiography that all 
settled with supplementary oxygen therapy and conserva-
tive management.
dIsCussIOn
We have demonstrated in a non- operable population of 
patients with predominantly subsegmental distribution 
CTEPH, as described at the national CTEPH MDT with 
experienced PEA surgeons present, that BPA delivered 
with a focused approach, concentrating on lower lobe 
predominantly subsegmental arteries, can achieve clini-
cally meaningful patient benefits safely with relatively few 
BPA treatment cycles.
Management of inoperable CtePH
The cornerstone of therapy is PEA surgery but up to 40% 
of patients with the disease are not surgical candidates, 
either due to associated comorbidity or disease burden 
that fails to justify the risk of major surgery or a distri-
bution of disease that is inaccessible.7 Patients with inop-
erable CTEPH have a less favourable prognosis and a 
high symptom burden.4 Recent, double blind, placebo 
controlled randomised controlled trials of the sGC 
stimulator—riociguat (Bayer) and ERA—macitentan 
(Actelion) over a period of 16 weeks have demonstrated 
modest but significant benefits.13 14 In the chest-1 trial 
mPAP fell by 10% and the PVR by one- third, while 6MWD 
increased by just over 10% in the riociguat arm and 33% 
of patients reported a one- grade improvement in FC. The 
safety and efficacy of riociguat appears to extend beyond 
2 years6 15 although longer- term mortality benefits have 
not been demonstrated and the treatments are lifelong 
and expensive.
efficacy of BPA
BPA may be more effective than medical therapy for 
the treatment of CTEPH,16 although the study popula-
tions may be heterogeneous and the first randomised 
controlled trial to study this: riociguat versus BPA in non- 
operable CTEPH (RACE) trial (NCT02634203), has not 
yet been published. Perhaps in reality the two are comple-
mentary—each treating different aspects of the disease 
process. In a systematic review of published longitudinal 
cohort studies comparing the ‘before’ and ‘after’ effects 
of BPA treatment delivered in mean of 2.5–6.6 sessions,20 
mPAP reduced by around 14.2 mm Hg, PVR by about 
300 dyn.s/cm5, the 6MWD was increased by around 67 m 
and FC fell by over one grade.
Our data are comparable despite some important 
differences in approach. First, our patients are from an 
experienced, national PEA centre and are truly inop-
erable with distal disease, as exemplified by the higher 
mPAP and PVR than other reported cohorts. This is 
important, as the response to BPA may be different when 
treating more proximal ‘surgical’ disease. Second, the 
number of BPA sessions we delivered and the number 
of treated vessels were fewer than other reported data.20 
We largely focused our BPA to vessels supplying the lower 
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Figure 4 The effect of BPA on the right heart as measured 
by (A) NT- pro BNP (one high outlier removed from the 
baseline plot) and (B) mid- cavity RV diameter. BPA, balloon 
pulmonary angioplasty; NT- pro BNP, N- terminal probrain 
natriuretic peptide; RV, right ventricular.
zones which receive a greater proportion of the cardiac 
output.25 Relieving the obstruction in these zones is likely 
to have a greater treatment effect on PVR, achieving 
symptomatic improvement with fewer treatment cycles. 
Third, the majority of our patients were on established 
evidence- based medical therapy, and therefore, the BPA 
effect we observed was additive. When BPA has been used 
sequentially in a similar manner, riociguat reduced mPAP 
from 49 to 43 mm Hg with a further reduction in mPAP 
to 34 mm Hg and PVR reductions of a further 30% after 
BPA.26 We saw similar improvements on top of medical 
therapy in the majority of our patients, confirming that 
BPA can further offload the right ventricle with clear 
synergy that may reflect their different disease modifying 
actions; BPA addresses subsegmental disease whereas 
medical therapy targets more distal and inaccessible 
vasculopathy. Fourth, we demonstrate clear benefits 
in RV geometry, size and function within 3 months of 
completing a course of BPA. This reverse RV remodel-
ling has been reported before27 28 and improvements in 
right heart size and function are predictive of adverse 
outcome.29 Finally, we clearly show for the first time that 
BPA significantly improves CAMPHOR scores predom-
inantly by improving subjective symptom and activity 
scores.
safety of BPA
BPA is an invasive treatment and is associated with compli-
cations which are reported at a rate of approximately 
10% of procedures in contemporary practice, although 
where routine CT follow- up is performed, this value may 
be higher.19 Determining the precise rate of complica-
tions is difficult as reporting varies from study to study 
and variable definitions have been used. A recent system-
atic review30 has confirmed in contemporary cohorts that 
mortality is generally below 2%. Mechanical circulatory 
support was required in 2.4%, endotracheal intubation 
in 4.6% and non- invasive ventilation in 22.5%. Other 
complications are generally reported per procedure; 
haemoptysis was reported in 13.5% and lung reperfusion 
injury (oedema) in 22%.
Our data compare favourably with that from other 
institutions. We have not observed any serious or life- 
threatening patient level complications and our rate of 
acute lung injury (haemoptysis and reperfusion injury) 
was lower than reported by others. This may reflect our 
approach, which does not aim at achieving full clearance, 
but rather targets important disease in basal segmental 
and subsegmental vessels, minimising the number of 
small and treacherous vessels treated which likely limits 
the procedure- related complications.
Future directions
We believe that BPA is now sufficiently developed that 
appropriately powered randomised controlled trials 
comparing subsegmental PEA versus BPA and BPA 
versus PH- targeted therapy can be planned to potentially 
broaden the indication for BPA in patients with CTEPH. 
However, consensus in the interpretation of imaging and 
standardisation of the surgical and BPA approach will 
be important to deliver meaningful comparisons. The 
immediate focus of registries should be to guide which 
endpoints to use and to define what constitutes a ‘good 
outcome’ for the patients with CTEPH; ideally this will be 
long- term survival with a good FC and QoL. Further work 
is also required to explore the nuances of the optimal BPA 
strategy. Clarity is required to delineate whether focused 
(as in our series) is superior to extensive and whether 
serial widespread balloon dilatations of increasing size 
is better than serial lobar treatments using balloons of 
appropriate size, as well as understanding the role of 
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adjunctive technologies. Ultimately the issue of cost effi-
cacy needs addressing to determine if lifelong PH- tar-
geted medical therapy remains necessary. It is unclear 
whether BPA alone will prevent disease progression from 
the associated vasculopathy, or whether ongoing PH- tar-
geted therapy after haemodynamically successful BPA is 
still necessary.
limitations
Oral anticoagulant was briefly interrupted to allow safe 
BPA therapy to be performed. This may have resulted in 
further clot formation and disease progression during 
the perioperative period. Follow- up CPET, 6MWD and 
echo data were obtained from standard clinical follow- up 
tests rather than dedicated research studies, and as a 
consequence, complete datasets were not available in all 
cases. Hence, some analyses may have been affected by 
missing variables. Finally, neither patients nor investiga-
tors were blinded to the allocated treatment and subjec-
tively reported data interpretation may have been influ-
enced by bias.
COnClusIOn
Focused BPA targeting basal subsegmental pulmonary 
arteries is safe and effective in treating inoperable CTEPH 
with clinically meaningful improvements in haemody-
namics, exercise capacity, ventilatory efficiency and RV 
dimensions that translate into symptomatic benefit and 
improved QoL for patients.
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